• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

Tagged: trial

  • Audio Journal of Oncology Volume 16 Number 8
    • in Oncology
    • — 15 Apr, 2008

    Audio Journal of Oncology Volume 16 Number 8

    Scientific Editors: George Canellos, Pat Price, Gordon McVie, Gianni Bonadonna

    In this edition:

    Bevacizumab and Survival in Metastatic Breast Cancer

    Source: N Engl J Med 357:26
    George Canellos, Dana-Farber Cancer Institute, Boston
    Progresson-free survival, but not overall survival, was …

    Read more
    Hormone Refractory Prostate Cancer: Increased Progression-Free Survival With Satraplatin and Prednisone
    • in Oncology
    • — 1 Feb, 2008

    Hormone Refractory Prostate Cancer: Increased Progression-Free Survival With Satraplatin and Prednisone

    Cora Sternberg
    Cora Sternberg
    REFERENCE: Abstract 4010, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007
    CORA STERNBERG, San Camillo and Forlanini Hospital, Rome
    Satraplatin could provide a new option for patients with hormone refractory prostate cancer, by giving
    …
    Read more
  • ATAC Trial: Anastrozole Still Superior At Over Eight Years’ Follow Up
    • in Oncology
    • — 15 Dec, 2007

    ATAC Trial: Anastrozole Still Superior At Over Eight Years’ Follow Up

    Jack Cuzick
    Jack Cuzick

    JACK CUZICK, Wolfson Institute of Preventive Medicine, London
    New data from the ATAC trial, which is testing anastrozole and tamoxifen in early breast cancer, have demonstrated the continued superiority of the aromatase inhibitor. Among other things, the data
    …
    Read more
    New Drug RAD001 Plus Letrozole In Neoadjuvant Therapy For Breast Cancer
    • in Oncology
    • — 15 Dec, 2007

    New Drug RAD001 Plus Letrozole In Neoadjuvant Therapy For Breast Cancer

    Jose Baselga
    Jose Baselga

    JOSE BASELGA, Vall d’Hebron Hospital, Barcelona
    RAD001, a drug targeted at the mTor pathway, has been combined with letrozole in a randomised phase II trial in breast cancer. The investigators saw more responses in the experimental arm, and
    …
    Read more
    • in Oncology
    • — 10 Dec, 2007

    Live Report from ASH:
    Oblimersen Extends Survival in Chronic Lymphocytic Leukemia

    Susan O’Brien
    Susan O’Brien

    SUSAN O’BRIEN, MD Anderson Cancer Center, Houston
    For patients with relapsed or refractory CLL, oblimersen extends survival when added to standard fludarabine/cyclophosphamide chemotherapy. Susan O’Brien presented data from this phase III trial to the American Society of Hematology
    …
    Read more
    • in Oncology
    • — 10 Dec, 2007

    Live Report from ASH:
    Interleukin-2 For Acute Myeloid Leukemia In First Remission?

    Jonathan Kolitz
    Jonathan Kolitz

    JONATHAN KOLITZ, Monter Cancer Center, Lake Success, NY
    GEORGE CANELLOS, Dana-Farber Cancer Institute

    For patients with acute myeloid leukemia in first remission, new data suggests that there may be a benefit from interleukin-2. Derek Thorne got the interim
    …
    Read more
  • New Drug AMG 531 Effective in Splenectomized Patients with Chronic Immune Thrombocytopenic Purpura
    • in General Medicine
    • — 9 Dec, 2007

    New Drug AMG 531 Effective in Splenectomized Patients with Chronic Immune Thrombocytopenic Purpura

    Terry Gernsheimer
    Terry Gernsheimer

    TERRY GERNSHEIMER, University of Washington Medical Center, Seattle
    An investigational drug AMG 531 has increased and sustained platelet counts in splenectomized patients with chronic immune thrombocytopenic purpura or ITP. This was in a placebo controlled phase III trial
    …
    Read more
    Large Risk Reduction For Rivaroxaban In Blood Clot Prevention
    • in General Medicine
    • — 9 Dec, 2007

    Large Risk Reduction For Rivaroxaban In Blood Clot Prevention

    Bengt Eriksson
    Bengt Eriksson

    REFERENCE: Abstract 6, American Society of Hematology Annual Meeting, December 8-11 2007, Atlanta
    BENGT ERIKSSON, Gothenburg University
    In a large phase III trial of patients having a hip replacement, the oral anticoagulant rivaroxaban has shown significant benefit when
    …
    Read more
  • TAXUS DES Trials Results: How Long Should Thienopyridine Be Used After Drug Eluting Stent?
    • in Cardiovascular
    • — 6 Nov, 2007

    TAXUS DES Trials Results: How Long Should Thienopyridine Be Used After Drug Eluting Stent?

    Gregg Stone
    Gregg Stone
    REFERENCE: Abstract 2357, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida
    GREGG STONE, Columbia University, New York
    New light has been thrown on the use of thienopyridine therapy after percutaneous intervention using drug-eluting stents. Gregg Stone
    …
    Read more
    Rosuvastatin: No Significant Benefit for Older Patients with Systolic Heart Failure: CORONA Study Results
    • in Cardiovascular
    • — 6 Nov, 2007

    Rosuvastatin: No Significant Benefit for Older Patients with Systolic Heart Failure: CORONA Study Results

    Ake Hjalmarson
    Ake Hjalmarson
    Gordon Tomaselli
    Gordon Tomaselli

    REFERENCE: Late Breaking Clinical Trials, Session 2, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida
    N Engl J Med 2007;357

    AKE HJALMARSON, Sahlgrenska University, Göteborg
    COMMENT: GORDON TOMASELLI, Johns Hopkins University, Baltimore

    The lipid
    …
    Read more
  • TRITON-TIMI 38 Prasugrel Or Clopidogrel In Percutaneous Intevention?
    • in Cardiovascular
    • — 5 Nov, 2007

    TRITON-TIMI 38 Prasugrel Or Clopidogrel In Percutaneous Intevention?

    Gordon Tomaselli
    Gordon Tomaselli
    Daniel Jones
    Daniel Jones

    REFERENCE: Late Breaking Clinical Trials 1, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida
    GORDON TOMASELLI, Johns Hopkins University, Baltimore
    COMMENT: DANIEL JONES, President, American Heart Association, University of Mississippi, Jackson

    A potential new
    …
    Read more
    Eptifibatide After PCI: Brief Infusion Is Just As Good
    • in Cardiovascular
    • — 5 Nov, 2007

    Eptifibatide After PCI: Brief Infusion Is Just As Good

    Anthony Fung
    Anthony Fung
    REFERENCE: Late Breaking Clinical Trials Session I, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida
    ANTHONY FUNG, University of British Columbia, Vancouver
    Brief courses of antiplatelet therapy with the glycoprotein 2b 3a inhibitor are just as
    …
    Read more
  • Next Page »
  • Sign up for AudioMedica.com news

    * = required field
    Speciality




  • Home
  • Tagged: trial

© COPYRIGHT 2020 AUDIOMEDICA.COM.